Updated clinical data from VISTA101 presented at SITC 2024.Monotherapy arm fully enrolled and combination arm expected to be fully enrolled by ...

CEL-SCI Corporation today announced that in a recent meeting the U.S. Food and Drug Administration (FDA) concurred with the Company's approach to patient selection using low PD-L1 tumor expression in ...

Enrollment on track in Phase 2 portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and KRAS ...

Thousands of Veterans have learned they're eligible for healthcare, food and housing benefits through enhanced interoperability between VA software and Epic. Caregivers using Epic's software can ...

Keytruda in early-stage triple-negative breast cancer led to immune-related adverse effects, including severe GI issues and ...

While immunotherapies have transformed treatment of many types of cancer, they do sometimes fail to have an impact – as Merck & Co has just observed in a study of Keytruda in head and neck cancer.

Prostate cancer has proved an elusive target for cancer immunotherapies, and Merck & Co's checkpoint inhibitor Keytruda is the latest to fall short in the disease in a phase 3 trial. Merck has ...

PharmaJet ®, a company that strives to improve the performance and outcomes of injectables with its enabling needle-free ...

Reprints are a great way for you to promote your Nature Portfolio article. Best of all, you now have more options for doing so than carrying around stacks of paper to share them! (Although—that ...

Nov. 8, 2024 — Researchers today are releasing the flagship dataset from an ambitious study of biomarkers and environmental factors that might influence the development of type 2 diabetes ...

Over the last few decades computing and the internet have revolutionized our ability to create, store and retrieve information on a whim. A global economy and instant communication have created an ...